Voquezna (vonoprazan) / Takeda, Otsuka, Phathom Pharma - LARVOL DELTA

Comparison of Cefuroxime-Based Dual Therapy With Quadruple Therapy in Helicobacter pylori-Infected Treatment-Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial. (PubMed, Helicobacter) - P=N/A | "CQT Was More Effective Than CDT for H. pylori Eradication, Which Might Be Recommended for Penicillin-Allergic Patients. If There Were Contraindications or Intolerance of CQT, CDT Would Be an Alternative."

Clinical • Journal • Infectious Disease

Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which's better? (PubMed, World J Gastroenterol) - "The HDDT based on vonoprazan demonstrated non-inferiority to the VAC triple regimen, suggesting its potential as a recommended first-line treatment for H. pylori eradication. While B-quadruple therapy showed better eradication rate than EA therapy, the latter proved non-inferior in mITT and PP analyses. Notably, antibiotic use within the preceding two years, adherence to treatment protocols, and patient residence emerged as critical factors influencing eradication success."

Clinical • Journal • Infectious Disease

JSHERO3: VA Dual Sequential Therapy (clinicaltrials.gov) - P4 | N=600 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P4 trial • Infectious Disease

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Phathom Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion

Rabeprazole- and vonoprazan-based dual therapies for H pylori eradication: effective with low side effects, rabeprazole being more cost-effective. (PubMed, Am J Transl Res) - "Dual therapy based on rabeprazole or vonoprazan effectively improves symptoms in patients with Hp infection, with relatively few adverse reactions and good treatment compliance. Additionally, rabeprazole-based dual therapy had a lower cost."

Adverse events • HEOR • Journal • Infectious Disease • Oncology • CRP • IL6 • TNFA

The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis. (PubMed, J Infect Public Health) - "According to ITT analysis and PP treatment analysis, the eradication rates of VA therapy were 88.81 % and 93.56 %, respectively. The incidence of adverse reactions was significantly lower (14.56 % vs 26.00 %, RR=0.57, 95 % CI: 0.48-0.67, p < 0.0001), and compliance was better (96.29 % vs 93.56 %, RR=1.03, 95 % CI: 1.01-1.05, p = 0.003), making it a reliable alternative therapy."

Clinical • Journal • Retrospective data • Review • Infectious Disease

Stability Indicating Hptlc - Densitometric Method for Estimation of Vonoprazan Fumarate. (PubMed, Drug Dev Ind Pharm) - "Forced degradation studies were performed. The method can be used for quality control and stability sample evaluation of vonoprazan fumarate."

Journal

Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial. (PubMed, Front Pharmacol) - P4 | "Smoking and previous eradication attempts were associated with the eradication failure of VA therapy. https://clinicaltrials.gov/, identifier NCT05469685."

HEOR • Journal • Infectious Disease

A Randomized Controlled Trial of Vonoprazan Combined with Dose-reduced Amoxicillin Dual Therapy for First-line Eradication of Helicobacter pylori (ChiCTR) - P4 | N=375 | Not yet recruiting | Sponsor: Jiangsu Provincial Hospital; Jiangsu Provincial Hospital

New P4 trial • Infectious Disease

Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on glycemic control in type 2 diabetes (ChiCTR) - P=N/A | N=150 | Not yet recruiting | Sponsor: Changzhou Second People's Hospital; Changzhou Second People's Hospital

New trial • Diabetes • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

A large-scale population study on the eradication effect of Helicobacter pylori (ChiCTR) - P=N/A | N=5000 | Not yet recruiting | Sponsor: Fujian Medical University; Fujian Medical University

New trial • Infectious Disease

Exploration of vonoprazan-amoxicillin in the treatment of Helicobacter pylori (ChiCTR) - P=N/A | N=504 | Recruiting | Sponsor: Peking University International Hospital; Peking University International Hospital

New trial • Infectious Disease

A clinical study on the treatment of Helicobacter pylori infection with a combination therapy of tegoprazan and amoxicillin (ChiCTR) - P=N/A | N=284 | Not yet recruiting | Sponsor: Fujian Provincial Hospital; Fujian Provincial Hospital

New trial • Infectious Disease

Vonoprazan combined with different doses of tetracycline dual therapy for Helicobacter pylori : a multicenter, non-inferiority, randomized controlled trial (ChiCTR) - P4 | N=372 | Not yet recruiting | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospital

New P4 trial • Infectious Disease

Efficacy Comparison of Vonoprazan Combined with Centralized Procurement versus Non-Centralized Procurement Amoxicillin Dual Therapy in Eradicating Helicobacter pylori: A Multicenter, Non-Inferiority, Randomized Controlled Study. (ChiCTR) - P4 | N=316 | Not yet recruiting | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospita

New P4 trial • Infectious Disease

A multicenter randomized controlled study: the eradication of Helicobacter pylori infection by therapy of Vonoprazan-Minocycline. (ChiCTR) - P4 | N=238 | Recruiting | Sponsor: Army Medical Center of PLA; Army Medical Center of PLA

New P4 trial • Infectious Disease

Comparison of Efficacy and Safety of Minocycline-Vonoprazan Dual Therapy in Helicobacter pylori Eradication: A Multicenter, Non-Inferiority, Randomized Controlled Study (ChiCTR) - P4 | N=260 | Not yet recruiting | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospital

New P4 trial • Infectious Disease

Efficacy and Safety of Doxycycline Combined with Vonoprazan in the Treatment of Helicobacter pylori Infection: A Multicenter, Non-Inferiority, Randomized Controlled Trial (ChiCTR) - P4 | N=260 | Not yet recruiting | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospital

New P4 trial • Infectious Disease

Efficacy and eradication effect of vonoprazan and high-dose amoxicillin dual therapy in CagA+VacA+ Helicobacter pylori infected patients. (PubMed, Curr Med Res Opin) - "The control group underwent PPI quadruple therapy (oral administration of esomeprazole, amoxicillin, clarithromycin, and colloidal bismuth subcitrate). The CagA+, VacA+, or CagA+VacA+ type patients showed no statistical difference in the incidence of adverse reactions, but the observation group showed a lower total incidence of adverse reactions than the control group. Vonoprazan combined with high-dose amoxicillin has better clinical efficacy and eradication effect for patients with CagA+VacA+ HP, along with reduced adverse reactions."

Journal • Infectious Disease

Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis. (PubMed, Front Microbiol) - "Our findings indicated that VA dual therapy provided a higher eradication rate, enhanced compliance, decreased adverse events, and lowered cost relative to BQT for patients with H. pylori infection. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024576738, identifier CRD42024576738 (PROSPERO)."

Journal • Retrospective data • Review • Infectious Disease

Clinical Impact of Vonoprazan on the Use of Midazolam during Upper Gastrointestinal Endoscopy (PubMed, Yakugaku Zasshi) - "The two patients groups also showed no statistically significant differences in the percentage of individuals who received oxygen administration during the examination or in post-examination oxygen saturation and blood pressure values. These results suggest that the use of MDZ for sedation during upper gastrointestinal endoscopy may have minimal clinical effects arising from drug interaction with VPZ."

Journal • Anesthesia • Gastrointestinal Disorder

The efficacy and safety of vonoprazan combined with semi-synthetic tetracycline in eradicating Helicobacter pylori: A multicenter, non-inferiority, randomized controlled study (ChiCTR) - P=N/A | N=345 | Not yet recruiting | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospital

New trial • Infectious Disease

Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication (clinicaltrials.gov) - P1 | N=136 | Not yet recruiting | Sponsor: Nanjing First Hospital, Nanjing Medical University

New P1 trial • Gastrointestinal Disorder • Infectious Disease

Efficacy of Potassium Competitive Acid Blockers (PCABs) vs Proton Pump Inhibitors (PPIs) for Healing of Duodenal Ulcers: A Systematic Review and Meta Analysis (APASL 2025) - "PCABs such as Vonoprazan, Tegoprazan, Soraprazan, Revaprazan, Keverprazan and Linaprazan are reversible, competitive antagonists of the H+/K+ ATPase that is seen to have more sustained acid suppression. PCABs such as Vonoprazan 20mg and Keverprazan 20mg are non inferior to PPIs in the healing of duodenal ulcers. Both classes of drugs had similar tolerability profiles. Table and Figure:Figure 1.Forest plot of PCAB vs PPI on healing of duodenal ulcers at Week 6 Figure 2.Forest plot of PCAB vs PPI on healing of duodenal ulcers at Week 4"

Retrospective data • Review • Chronic Kidney Disease • Musculoskeletal Diseases • Nephrology • Orthopedics • Peptic Ulcer • Renal Disease

Which of vonoprazan alone or intravenous proton pump inhibitor followed by vonoprazan is optimal for reducing delayed bleeding in gastric endoscopic submucosal dissection? (PubMed, Digestion) - "Both vonoprazan alone and intravenous PPI followed by vonoprazan might be acceptable in gastric ESD when antithrombotic agents were not administered, whereas intravenous PPI followed by vonoprazan might be favorable in patients with antithrombotic agents."

Journal